Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust Corp

Northern Trust Corp boosted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 5.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,314,871 shares of the biopharmaceutical company’s stock after acquiring an additional 68,174 shares during the period. Northern Trust Corp owned about 0.84% of Ocular Therapeutix worth $11,229,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of OCUL. MetLife Investment Management LLC raised its holdings in shares of Ocular Therapeutix by 2.7% during the fourth quarter. MetLife Investment Management LLC now owns 92,734 shares of the biopharmaceutical company’s stock valued at $792,000 after buying an additional 2,454 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Ocular Therapeutix by 10.0% during the fourth quarter. Teacher Retirement System of Texas now owns 27,777 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 2,526 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ocular Therapeutix by 11.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 3,347 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Ocular Therapeutix by 1.0% during the fourth quarter. Wellington Management Group LLP now owns 467,352 shares of the biopharmaceutical company’s stock valued at $3,991,000 after buying an additional 4,488 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Ocular Therapeutix by 19.3% during the fourth quarter. Sei Investments Co. now owns 27,742 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 4,496 shares during the last quarter. Institutional investors own 59.21% of the company’s stock.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. The trade was a 0.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard L. Md Lindstrom acquired 10,000 shares of the stock in a transaction on Thursday, May 8th. The shares were purchased at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares in the company, valued at approximately $1,202,019.84. This represents a 6.15% increase in their position. The disclosure for this purchase can be found here. 3.50% of the stock is currently owned by company insiders.

Ocular Therapeutix Price Performance

Shares of NASDAQ:OCUL opened at $7.22 on Friday. Ocular Therapeutix, Inc. has a 12 month low of $4.79 and a 12 month high of $11.78. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -5.47 and a beta of 1.51. The stock’s 50 day moving average price is $7.41 and its 200 day moving average price is $8.15. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The business had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. Equities research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on OCUL shares. Needham & Company LLC cut their price target on Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Royal Bank of Canada started coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They set an “outperform” rating and a $17.00 price target on the stock. William Blair started coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an “outperform” rating on the stock. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Finally, JMP Securities set a $19.00 target price on Ocular Therapeutix in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.25.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.